What is Bicara Therapeutics's cost not yet recognized?

Bicara Therapeutics (BCAX) reported cost not yet recognized of $72.5M in Q1 2026.

How has Bicara Therapeutics's cost not yet recognized changed year-over-year?

Bicara Therapeutics's cost not yet recognized increased by 112.6% year-over-year, from $34.1M to $72.5M.

Viridian Therapeutics, Inc.VRDN

——

Aurinia PharmaceuticalsAUPH

——

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Market cap$1.68B+81.4%

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Bicara Therapeutics's cost not yet recognized?: Bicara Therapeutics (BCAX) reported cost not yet recognized of $72.5M in Q1 2026.
How has Bicara Therapeutics's cost not yet recognized changed year-over-year?: Bicara Therapeutics's cost not yet recognized increased by 112.6% year-over-year, from $34.1M to $72.5M.